Clinical Trial Update: Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating mesylate apatinib combined with irinotecan for recurrent small cell lung cancer is in progress, with status currently UNKNOW…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• mesylate apatinib (apatinib)

Snippet

Sponsor: Beijing Chest Hospital | Conditions: Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN